1. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial;van Lunzen;Lancet Infect Dis,2012
2. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results–SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, USA; Sept 9–12, 2012. H-556b.
3. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet,2013
4. Oliveira M, Moisi D, Ibanescu R-I, et al. Novel mutational changes involved in delayed development of dolutegravir resistance in HIV-1 B and non-B subtypes during in vitro drug selection. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, USA; March 5–8, 2012, Seattle. 692.
5. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule;Hurt;Antivir Ther,2011